Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; ...
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in ...
Taunton Daily Gazette1d
Raynham woman's remarkable story of surviving as a 'German Wolf Child.' What it was like
She was a little girl. Her world was turned upside down. But she maintained her determination and hopefulness,” said friend and author Kristen Arute ...
In Germany, ‘Orphaned’ by U.S., Shock Gives Way to Action
No country in Europe is as much a product of enlightened postwar American diplomacy. Now adrift, it has begun to reckon with ...
TMCnet4d
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
-- Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete ...
The Lancet4d
Advancing policies for rare diseases in Europe
Fostering dialogue between neurologists, researchers, patient representatives, and policymakers is an important step towards ...
TMCnet5d
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment
Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity.